Hepatitis C Virus (HCV)

all Activators (1) Inhibitors (254)

CAS No.	Product Name	Inquiry
1613589-04-0	4′-C-Fluoro-2′-C-methyluridine 4'-C-Fluoro-2'-C-methyluridine is a modified form of uridine where the oxygen at the 2' position of the ribose sugar is replaced by a methyl group, and a fluorine atom is attached to the carbon at the 4' position of the ribose sugar. This modification enhances the stability and binding affinity of the nucleotide, making it useful in various molecular biology applications, including RNA structure studies, antisense oligonucleotide design, and as a substrate for enzymatic reactions in RNA biochemistry research.
101784-44-5	Antiviral agent 52 Hepatitis C is a liver infection caused by the hepatitis C virus (HCV). It is a blood-borne virus, which can cause both acute and chronic hepatitis. CAY10704 is a potent inhibitor of hepatitis C virus (HCV) infection with EC50 of 17 nM. It displays good pharmacokinetics in mice with preferential liver distribution without significant hepatotoxicity. CAY10704 is also selective for HCV over dengue virus with EC50 of 4.62 µM.
	Artemisinin-d4 Artemisinin-d4 (Qinghaosu-d4) is the deuterium labeled Artemisinin. Artemisinin (Qinghaosu), a sesquiterpene lactone, is an anti-malarial drug isolated from the aerial parts of Artemisia annua L. plants. It inhibits AKT signaling pathway by decreasing pAKT in a dose-dependent manner. Artemisinin reduces cancer cell proliferation, migration, invasion, tumorigenesis and metastasis and has neuroprotective effects.
	Catenulopyrizomicin A
	Clemizole-d4
	Coblopasvir Coblopasvir (KW-136) is a pangenotypic non-structural protein 5A (NS5A) inhibitor. Coblopasvir can be used for research of chronic hepatitis C virus infection
	Daclatasvir-d16 Daclatasvir-d16 is a labelled Daclatasvir which inhibits the HCV protein NS5A, and thus can be used as a drug candidate for the treatment of hepatitis C (HCV).
	FNC-TP-trisodium FNC-TP trisodium is the intracellular active form of FNC. FNC is a potent nucleoside reverse transcriptase inhibitor (NRTI), with antiviral activity on HIV, HBV and HCV.
	HCV-IN-38 HCV-IN-38 is a potent, selective and orally active HCV inhibitor (EC50=15 nM, SI=431). HCV-IN-38 has high anti-HCV activity and low cytotoxicity. HCV-IN-38 has a good safety and oral pharmacokinetic profile.
	Hypericin-d10 Hypericin-d10 is the isotope labelled analog of Hypericin.
	Hypericin-d2 Hypericin-d2 is deuterium labeled Hypericin.
446826-86-4	KIN1400 KIN1400 is an IRF3 activator with antiviral activity. It induces IRF3-dependent innate immune gene expression such as RIG-1, MDA5, IFIT1, IFIT2, IFITM1, OAS3, and Mx1 in THP-1 cells stimulated with phorbol 12-myristate 13-acetate (PMA). It also inhibits replication of HCV, West Nile virus, and Paramyxoviridae (RCV, NV).
	Ledipasvir-hydrochloride Ledipasvir (GS-5885) hydrochloride is an inhibitor of the hepatitis C virus NS5A, with EC50s of 34 pM and 4 pM against genotype 1a and 1b replicon, respectively. Ledipasvir hydrochloride is also a SARS-CoV 3CLpro inhibitor with an IC50 of 1.62 M.
	NHC-diphosphate triammonium NHC-triphosphate triammonium is a weak alternative substrate for the viral polymerase and can be incorporated into HCV replicon RNA.
	NHC-diphosphate-triammonium NHC-triphosphate triammonium is an active phosphorylated intracellular metabolite of β-d-N4-Hydroxycytidine (NHC) (HY-125033) as a triphosphate form. NHC-triphosphate triammonium is a weak alternative substrate for the viral polymerase and can be incorporated into HCV replicon RNA.
	NHC-triphosphate tetraammonium NHC-triphosphate tetraammonium is a weak alternative substrate for the viral polymerase and can be incorporated into HCV replicon RNA.
	NHC-triphosphate-tetraammonium NHC-triphosphate tetraammonium is an active phosphorylated intracellular metabolite of β-d-N4-Hydroxycytidine (NHC)(HY-125033) as a triphosphate form. NHC-triphosphate tetraammonium is a weak alternative substrate for the viralpolymerase and can be incorporated into HCV replicon RNA.
	NHC-triphosphate-tetrasodium NHC-triphosphate tetrasodium is an active phosphorylated intracellular metabolite of β-d-N4-Hydroxycytidine (NHC) (HY-125033) as a triphosphate form. NHC-triphosphate tetrasodium is a weak alternative substrate for the viral polymerase and can be incorporated into HCV replicon RNA.
1353900-92-1	Pibrentasvir Pibrentasvir is an antiviral agent that inhibits HCV non-structural protein 5A (NS5A). It inhibits HCV RNA replication and viron assembly. In combination with glecaprevir, a HCV NS3/4A protease inhibitor, pibrentasvir is used to treat patients with HCV infections who experienced therapeutic failure from other NS5A inhibitors.
	PSI-6206-d1,13C,15N2

※ Please kindly note that our services are for research use only.